Registro:

Referencias:

• Kissick, H.T., Sanda, M.G., The role of active vaccination in cancer immunotherapy: lessons from clinical trials (2015) Curr Opin Immunol, 35, pp. 15-22
• Liu, C.-C., Ye, X.-S., Carbohydrate-based cancer vaccines: target cancer with sugar bullets (2012) Glycoconj J, 29 (5-6), pp. 259-271
• Miller, J.F.A.P., Sadelain, M., The journey from discoveries in fundamental immunology to cancer immunotherapy (2015) Cancer Cell, 27 (4), pp. 439-449
• Koster, B.D., de Gruijl, T.D., van den Eertwegh, A.J.M., Recent developments and future challenges in immune checkpoint inhibitory cancer treatment (2015) Curr Opin Oncol, 27 (6), pp. 482-488
• Gubin, M.M., Zhang, X., Schuster, H., Caron, E., Ward, J.P., Noguchi, T., Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens (2014) Nature, 515 (7528), pp. 577-581
• Hart, G.W., Copeland, R.J., Glycomics hits the big time (2010) Cell, 143 (5), pp. 672-676
• Corfield, A.P., Berry, M., Glycan variation and evolution in the eukaryotes (2015) Trends Biochem Sci, 40 (7), pp. 351-359
• Stanley, P., Schachter, H., Taniguchi, N., N-Glycans (2009) Essentials of Glycobiology, , http://www.ncbi.nlm.nih.gov/books/NBK1917/, Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, editors, 2nd edn, Chapter 8. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press
• Pinho, S.S., Reis, C.A., Glycosylation in cancer: mechanisms and clinical implications (2015) Nat Rev Cancer, 15 (9), pp. 540-555
• Ohtsubo, K., Marth, J.D., Glycosylation in cellular mechanisms of health and disease (2006) Cell, 126 (5), pp. 855-867
• Mariño, K., Saldova, R., Adamczyk, B., Rudd, P.M., Changes in serum N-glycosylation profiles: functional significance and potential for diagnostics (2012) Carbohydrate Chemistry, 37, pp. 57-93. , Rauter AP, Lindhorst TK, editors. Cambridge: The Royal Society of Chemistrys
• Reis, C.A., Osorio, H., Silva, L., Gomes, C., David, L., Alterations in glycosylation as biomarkers for cancer detection (2010) J Clin Pathol, 63 (4), pp. 322-329
• Peracaula, R., Barrabás, S., Sarrats, A., Rudd, P.M., de Llorens, R., Altered glycosylation in tumours focused to cancer diagnosis (2008) Dis Markers, 25 (4-5), pp. 207-218
• Häuselmann, I., Borsig, L., Altered tumor-cell glycosylation promotes metastasis (2014) Front Oncol, 4, p. 28
• Christiansen, M.N., Chik, J., Lee, L., Anugraham, M., Abrahams, J.L., Packer, N.H., Cell surface protein glycosylation in cancer (2014) Proteomics, 14 (4-5), pp. 525-546
• Daniotti, J.L., Vilcaes, A.A., Torres Demichelis, V., Ruggiero, F.M., Rodriguez-Walker, M., Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches (2013) Front Oncol, 3, p. 306
• Vasconcelos-dos-Santos, A., Oliveira, I.A., Lucena, M.C., Mantuano, N.R., Whelan, S.A., Dias, W.B., Biosynthetic machinery involved in aberrant glycosylation: promising targets for developing of drugs against cancer (2015) Front Oncol, 5, p. 138
• Brooks, S.A., Carter, T.M., Royle, L., Harvey, D.J., Fry, S.A., Kinch, C., Altered glycosylation of proteins in cancer: what is the potential for new anti-tumour strategies (2008) Anticancer Agents Med Chem, 8 (1), pp. 2-21
• Boligan, K., Mesa, C., Fernandez, L., von Gunten, S., Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense (2015) Cell Mol Life Sci, 72 (7), pp. 1231-1248
• Mechref, Y., Hu, Y., Garcia, A., Hussein, A., Defining putative glycan cancer biomarkers by mass spectrometry (2012) Bioanalysis, 4 (20), pp. 2457-2469
• Harvey, D.J., Merry, A.H., Royle, L., Campbell, M.P., Dwek, R.A., Rudd, P.M., Proposal for a standard system for drawing structural diagrams of N-and O-linked carbohydrates and related compounds (2009) Proteomics, 9 (15), pp. 3796-3801
• Patani, N., Jiang, W., Mokbel, K., Prognostic utility of glycosyltransferase expression in breast cancer (2008) Cancer Genomics Proteomics, 5 (6), pp. 333-340
• Gomes, J., Marcos, N.T., Berois, N., Osinaga, E., Magalhães, A., Pinto-de-Sousa, J., Expression of UDP-N-acetyl-d-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma (2009) J Histochem Cytochem, 57 (1), pp. 79-86
• Berois, N., Gattolliat, C.-H., Barrios, E., Capandeguy, L., Douc-Rasy, S., Valteau-Couanet, D., GALNT9 gene expression is a prognostic marker in neuroblastoma patients (2013) Clin Chem, 59 (1), pp. 225-233
• Chen, Z., Gulzar, Z.G., St. Hill, C.A., Walcheck, B., Brooks, J.D., Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers (2014) Prostate, 74 (10), pp. 1059-1067
• Anugraham, M., Jacob, F., Nixdorf, S., Everest-Dass, A.V., Heinzelmann-Schwarz, V., Packer, N.H., Specific glycosylation of membrane proteins in epithelial ovarian cancer cell lines: glycan structures reflect gene expression and DNA methylation status (2014) Mol Cell Proteomics, 13 (9), pp. 2213-2232
• Wang, Y., Fukuda, T., Isaji, T., Lu, J., Im, S., Hang, Q., Loss of a1,6-fucosyltransferase inhibits chemical-induced hepatocellular carcinoma and tumorigenesis by down-regulating several cell signaling pathways (2015) FASEB J, 29 (8), pp. 3217-3227
• Chia, J., Goh, G., Bard, F., Short O-GalNAc glycans: regulation and role in tumor development and clinical perspectives (2016) Biochim Biophys Acta
• Taniguchi, N., Kizuka, Y., Glycans and cancer: role of N-glycans in cancer biomarker, progression and metastasis, and therapeutics (2015) Adv Cancer Res, 126, pp. 11-51
• Saldova, R., Dempsey, E., Pérez-Garay, M., Mariño, K., Watson, J.A., Blanco-Fernández, A., 5-AZA-2'-deoxycytidine induced demethylation influences N-glycosylation of secreted glycoproteins in ovarian cancer (2011) Epigenetics, 6 (11), pp. 1362-1372
• Bassagañas, S., Allende, H., Cobler, L., Ortiz, M.R., Llop, E., de Bolós, C., Inflammatory cytokines regulate the expression of glycosyltransferases involved in the biosynthesis of tumor-associated sialylated glycans in pancreatic cancer cell lines (2015) Cytokine, 75 (1), pp. 197-206
• Venkitachalam, S., Revoredo, L., Varadan, V., Fecteau, R.E., Ravi, L., Lutterbaugh, J., Biochemical and functional characterization of glycosylation-associated mutational landscapes in colon cancer (2016) Sci Rep, 6, p. 23642
• Dimitroff, C.J., Galectin-binding O-glycosylations as regulators of malignancy (2015) Cancer Res, 75 (16), pp. 3195-3202
• Croci, D.O., Cerliani, J.P., Dalotto-Moreno, T., Mendez-Huergo, S.P., Mascanfroni, I.D., Dergan-Dylon, S., Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors (2014) Cell, 156 (4), pp. 744-758
• Crocker, P.R., Paulson, J.C., Varki, A., Siglecs and their roles in the immune system (2007) Nat Rev Immunol, 7 (4), pp. 255-266
• Rachel, H., Chang-Chun, L., Recent advances toward the development of inhibitors to attenuate tumor metastasis via the interruption of lectin-ligand interactions (2013) Advances in Carbohydrate Chemistry and Biochemistry, pp. 125-207. , Derek H, editor. Oxford: Academic Press
• Magesh, S., Ando, H., Tsubata, T., Ishida, H., Kiso, M., High-affinity ligands of siglec receptors and their therapeutic potentials (2011) Curr Med Chem, 18 (23), pp. 3537-3550
• Pillai, S., Netravali, I.A., Cariappa, A., Mattoo, H., Siglecs and immune regulation (2012) Annu Rev Immunol, 30 (1), pp. 357-392
• Macauley, M.S., Crocker, P.R., Paulson, J.C., Siglec-mediated regulation of immune cell function in disease (2014) Nat Rev Immunol, 14 (10), pp. 653-666
• Merli, M., Ferrario, A., Maffioli, M., Arcaini, L., Passamonti, F., Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma (2015) Expert Opin Investig Drugs, 24 (7), pp. 897-912
• Jandus, C., Boligan, K.F., Chijioke, O., Liu, H., Dahlhaus, M., Démoulins, T., Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance (2014) J Clin Invest, 124 (4), pp. 1810-1820
• Linenberger, M.L., CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance (2004) Leukemia, 19 (2), pp. 176-182
• Takamiya, R., Ohtsubo, K., Takamatsu, S., Taniguchi, N., Angata, T., The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway (2013) Glycobiology, 23 (2), pp. 178-187
• Swanson, B.J., McDermott, K.M., Singh, P.K., Eggers, J.P., Crocker, P.R., Hollingsworth, M.A., MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion (2007) Cancer Res, 67 (21), pp. 10222-10229
• Mitra, N., Banda, K., Altheide, T.K., Schaffer, L., Johnson-Pais, T.L., Beuten, J., SIGLEC12, a human-specific segregating (Pseudo)gene, encodes a signaling molecule expressed in prostate carcinomas (2011) J Biol Chem, 286 (26), pp. 23003-23011
• Cummings, R.D., McEver, R.P., C-type lectins (2009) Essentials of Glycobiology, , http://www.ncbi.nlm.nih.gov/books/NBK1943/, Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, editors. Chapter 31. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press
• Chen, M., Geng, J.-G., P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis (2006) Arch Immunol Ther Exp (Warsz), 54 (2), pp. 75-84
• Barthel, S.R., Gavino, J.D., Descheny, L., Dimitroff, C.J., Targeting selectins and selectin ligands in inflammation and cancer (2007) Expert Opin Ther Targets, 11 (11), pp. 1473-1491
• Chen, Z.P., Jing, Y.M.S., Song, B.M.S., Han, Y.M.S., Chu, Y.P., Chemically modified heparin inhibits in vitro L-selectin-mediated human ovarian carcinoma cell adhesion (2009) Int J Gynecol Cancer, 19 (4), pp. 540-546
• Vasta, G.R., Galectins as pattern recognition receptors: structure, function, and evolution (2012) Adv Exp Med Biol, 946, pp. 21-36
• Huflejt, M., Leffler, H., Galectin-4 in normal tissues and cancer (2003) Glycoconj J, 20 (4), pp. 247-255
• Oka, T., Murakami, S., Arata, Y., Hirabayashi, J., Kasai, K.-I., Wada, Y., Identification and cloning of rat galectin-2: expression is predominantly in epithelial cells of the stomach (1999) Arch Biochem Biophys, 361 (2), pp. 195-201
• Madsen, P., Rasmussen, H.H., Flint, T., Gromov, P., Kruse, T.A., Honoré, B., Cloning, expression, and chromosome mapping of human galectin-7 (1995) J Biol Chem, 270 (11), pp. 5823-5829
• Dyer, K.D., Rosenberg, H.F., Eosinophil charcot-leyden crystal protein binds to beta-galactoside sugars (1996) Life Sci, 58 (23), pp. 2073-2082
• Yang, R.-Y., Hsu, D.K., Yu, L., Chen, H.-Y., Liu, F.-T., Galectin-12 is required for adipogenic signaling and adipocyte differentiation (2004) J Biol Chem, 279 (28), pp. 29761-29766
• Hotta, K., Funahashi, T., Matsukawa, Y., Takahashi, M., Nishizawa, H., Kishida, K., Galectin-12, an adipose-expressed galectin-like molecule possessing apoptosis-inducing activity (2001) J Biol Chem, 276 (36), pp. 34089-34097
• Rabinovich Gabriel, A., Croci Diego, O., Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer (2012) Immunity, 36 (3), pp. 322-335
• Salatino, M., Rabinovich, G.A., Fine-tuning antitumor responses through the control of galectin-glycan interactions: an overview (2011) Suppression and Regulation of Immune Responses: Methods and Protocols, pp. 355-374. , Cuturi CM, Anegon I, editors. Totowa, NJ: Humana Press
• Paz, A., Haklai, R., Elad-Sfadia, G., Ballan, E., Kloog, Y., Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation (2001) Oncogene, 20, pp. 7486-7493
• Harazono, Y., Kho, D.H., Balan, V., Nakajima, K., Zhang, T., Hogan, V., Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells (2014) Oncotarget, 5 (20), pp. 9992-10001
• Kopitz, J., von Reitzenstein, C., André, S., Kaltner, H., Uhl, J., Ehemann, V., Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3 (2001) J Biol Chem, 276 (38), pp. 35917-35923
• Markowska, A.I., Liu, F.-T., Panjwani, N., Galectin-3 is an important mediator of VEGF-and bFGF-mediated angiogenic response (2010) J Exp Med, 207 (9), pp. 1981-1993
• Thijssen, V.L., Barkan, B., Shoji, H., Aries, I.M., Mathieu, V., Deltour, L., Tumor cells secrete galectin-1 to enhance endothelial cell activity (2010) Cancer Res, 70 (15), pp. 6216-6224
• Dalotto-Moreno, T., Croci, D.O., Cerliani, J.P., Martinez-Allo, V.C., Dergan-Dylon, S., Méndez-Huergo, S.P., Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease (2013) Cancer Res, 73 (3), pp. 1107-1117
• Hittelet, A., Legendre, H., Nagy, N., Bronckart, Y., Pector, J.-C., Salmon, I., Upregulation of galectins-1 and-3 in human colon cancer and their role in regulating cell migration (2003) Int J Cancer, 103 (3), pp. 370-379
• Rubinstein, N., Alvarez, M., Zwirner, N.W., Toscano, M.A., Ilarregui, J.M., Bravo, A., Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege (2004) Cancer Cell, 5 (3), pp. 241-251
• Toscano, M.A., Bianco, G.A., Ilarregui, J.M., Croci, D.O., Correale, J., Hernandez, J.D., Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death (2007) Nat Immunol, 8 (8), pp. 825-834
• Stowell, S.R., Qian, Y., Karmakar, S., Koyama, N.S., Dias-Baruffi, M., Leffler, H., Differential roles of galectin-1 and galectin-3 in regulating leukocyte viability and cytokine secretion (2008) J Immunol, 180 (5), pp. 3091-3102
• Liu, F.-T., Rabinovich, G.A., Galectins as modulators of tumour progression (2005) Nat Rev Cancer, 5 (1), pp. 29-41
• Perillo, N.L., Pace, K.E., Seilhamer, J.J., Baum, L.G., Apoptosis of T cells mediated by galectin-1 (1995) Nature, 378 (6558), pp. 736-739
• Ilarregui, J.M., Croci, D.O., Bianco, G.A., Toscano, M.A., Salatino, M., Vermeulen, M.E., Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10 (2009) Nat Immunol, 10 (9), pp. 981-991
• Thiemann, S., Man, J.H., Chang, M.H., Lee, B., Baum, L.G., Galectin-1 regulates tissue exit of specific dendritic cell populations (2015) J Biol Chem, 290, pp. 22662-22677
• Kuo, P.-L., Hung, J.-Y., Huang, S.-K., Chou, S.-H., Cheng, D.-E., Jong, Y.-J., Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway (2011) J Immunol, 186 (3), pp. 1521-1530
• Astorgues-Xerri, L., Riveiro, M.E., Tijeras-Raballand, A., Serova, M., Neuzillet, C., Albert, S., Unraveling galectin-1 as a novel therapeutic target for cancer (2014) Cancer Treat Rev, 40 (2), pp. 307-319
• Ito, K., Stannard, K., Gabutero, E., Clark, A., Neo, S.-Y., Onturk, S., Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment (2012) Cancer Metastasis Rev, 31 (3-4), pp. 763-778
• Belanis, L., Plowman, S.J., Rotblat, B., Hancock, J.F., Kloog, Y., Galectin-1 is a novel structural component and a major regulator of H-Ras nanoclusters (2008) Mol Biol Cell, 19 (4), pp. 1404-1414
• Nakahara, S., Oka, N., Raz, A., On the role of galectin-3 in cancer apoptosis (2005) Apoptosis, 10 (2), pp. 267-275
• Raz, A., Zhu, D., Hogan, V., Shah, N., Raz, T., Karkash, R., Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis (1990) Int J Cancer, 46 (5), pp. 871-877
• Oliveira, J.T.D., Ribeiro, C., Gärtner, F., Role of galectin-3 in cancer metastasis (2015) Glycobiol Insights, 5, pp. 1-13
• Fukumori, T., Kanayama, H.-O., Raz, A., The role of galectin-3 in cancer drug resistance (2007) Drug Resist Updat, 10 (3), pp. 101-108
• Glinsky, V.V., Glinsky, G.V., Rittenhouse-Olson, K., Huflejt, M.E., Glinskii, O.V., Deutscher, S.L., The role of thomsen-friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium (2001) Cancer Res, 61 (12), pp. 4851-4857
• Demotte, N., Stroobant, V., Courtoy, P.J., Van Der Smissen, P., Colau, D., Luescher, I.F., Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes (2008) Immunity, 28 (3), pp. 414-424
• Tsuboi, S., Sutoh, M., Hatakeyama, S., Hiraoka, N., Habuchi, T., Horikawa, Y., A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans (2011) EMBO J, 30 (15), pp. 3173-3185
• Park, G.B., Kim, D., Kim, Y., Lee, H., Kim, C.W., Hur, D.Y., Silencing of galectin-3 represses osteosarcoma cell migration and invasion through inhibition of FAK/Src/Lyn activation and β-catenin expression and increases susceptibility to chemotherapeutic agents (2015) Int J Oncol, 46, pp. 185-194
• Moon, B.-K., Lee, Y.J., Battle, P., Jessup, J.M., Raz, A., Kim, H.-R.C., Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis (2001) Am J Pathol, 159 (3), pp. 1055-1060
• Harazono, Y., Hyo Kho, D., Balan, V., Nakajima, K., Hogan, V., Raz, A., Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling (2015) Oncotarget, 6 (23), pp. 19592-19604
• Harazono, Y., Nakajima, K., Raz, A., Why anti-Bcl-2 clinical trials fail: a solution (2014) Cancer Metastasis Rev, 33 (1), pp. 285-294
• Borsig, L., Wong, R., Feramisco, J., Nadeau, D.R., Varki, N.M., Varki, A., Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis (2001) Proc Natl Acad Sci U S A, 98 (6), pp. 3352-3357
• Kozlowski, E.O., Pavao, M.S.G., Borsig, L., Ascidian dermatan sulfates attenuate metastasis, inflammation and thrombosis by inhibition of P-selectin (2011) J Thromb Haemost, 9 (9), pp. 1807-1815
• Wang, R., Huang, J., Wei, M., Zeng, X., The synergy of 6-O-sulfation and N-or 3-O-sulfation of chitosan is required for efficient inhibition of P-selectin-mediated human melanoma A375 cell adhesion (2010) Biosci Biotechnol Biochem, 74 (8), pp. 1697-1700
• Perez-Castells, J., Hernandez-Gay, J.J., Denton, R.W., Tony, K.A., Mootoo, D.R., Jimenez-Barbero, J., The conformational behaviour and P-selectin inhibition of fluorine-containing sialyl LeX glycomimetics (2007) Org Biomol Chem, 5 (7), pp. 1087-1092
• Shodai, T., Suzuki, J., Kudo, S., Itoh, S., Terada, M., Fujita, S., Inhibition of P-selectin-mediated cell adhesion by a sulfated derivative of sialic acid (2003) Biochem Biophys Res Commun, 312 (3), pp. 787-793
• Gouge-Ibert, V., Pierry, C., Poulain, F., Serre, A.-L., Largeau, C., Escriou, V., Synthesis of fluorinated C-mannopeptides as sialyl Lewisx mimics for E-and P-selectin inhibition (2010) Bioorg Med Chem Lett, 20 (6), pp. 1957-1960
• Filser, C., Kowalczyk, D., Jones, C., Wild, M.K., Ipe, U., Vestweber, D., Synthetic glycopeptides from the E-selectin ligand 1 with varied sialyl Lewisx structure as cell-adhesion inhibitors of E-selectin (2007) Angew Chem Int Ed, 46 (12), pp. 2108-2111
• Esko, J.D., Lindahl, U., Molecular diversity of heparan sulfate (2001) J Clin Invest, 108 (2), pp. 169-173
• Bendas, G., Borsig, L., Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins (2012) Int J Cell Biol, 2012, p. 10
• Hostettler, N., Naggi, A., Torri, G., Ishai-Michaeli, R., Casu, B., Vlodavsky, I., P-selectin-and heparanase-dependent antimetastatic activity of non-anticoagulant heparins (2007) FASEB J, 21 (13), pp. 3562-3572
• Kragh, M., Binderup, L., Vig Hjarnaa, P., Bramm, E., Johansen, K.B., Frimundt Petersen, C., Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth (2005) Oncol Rep, 14, pp. 99-104
• Mousa, S.A., Petersen, L.J., Anti-cancer properties of low-molecular-weight heparin: preclinical evidence (2009) Thromb Haemost, 102 (8), pp. 258-267
• Belting, M., Glycosaminoglycans in cancer treatment (2014) Thromb Res, 133, pp. S95-S101
• Denton, R.W., Cheng, X., Tony, K.A., Dilhas, A., Hernández, J.J., Canales, A., C-disaccharides as probes for carbohydrate recognition-investigation of the conformational requirements for binding of disaccharide mimetics of sialyl Lewis X (2007) European J Org Chem, 2007 (4), pp. 645-654
• Nicoll, G., Avril, T., Lock, K., Furukawa, K., Bovin, N., Crocker, P.R., Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and-independent mechanisms (2003) Eur J Immunol, 33 (6), pp. 1642-1648
• Attrill, H., Takazawa, H., Witt, S., Kelm, S., Isecke, R., Brossmer, R., The structure of siglec-7 in complex with sialosides: leads for rational structure-based inhibitor design (2006) Biochem J, 397 (2), pp. 271-278
• Kelm, S., Gerlach, J., Brossmer, R., Danzer, C.-P., Nitschke, L., The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound (2002) J Exp Med, 195 (9), pp. 1207-1213
• Chen, W.C., Completo, G.C., Sigal, D.S., Crocker, P.R., Saven, A., Paulson, J.C., In vivo targeting of B-cell lymphoma with glycan ligands of CD22 (2010) Blood, 115 (23), pp. 4778-4786
• Kelm, S., Madge, P., Islam, T., Bennett, R., Koliwer-Brandl, H., Waespy, M., C-4 modified sialosides enhance binding to siglec-2 (CD22): towards potent Siglec inhibitors for immunoglycotherapy (2013) Angew Chem Int Ed, 52 (13), pp. 3616-3620
• Blanchard, H., Yu, X., Collins, P.M., Bum-Erdene, K., Galectin-3 inhibitors: a patent review (2008-present) (2014) Expert Opin Ther Pat, 24 (10), pp. 1053-1065
• Blanchard, H., Bum-Erdene, K., Hugo, M.W., Inhibitors of galectins and implications for structure-based design of galectin-specific therapeutics (2014) Aust J Chem, 67 (12), pp. 1763-1779
• Tellez-Sanz, R., Garcia-Fuentes, L., Vargas-Berenguel, A., Human galectin-3 selective and high affinity inhibitors. Present state and future perspectives (2013) Curr Med Chem, 20 (24), pp. 2979-2990
• Ingrassia, L., Nshimyumukiza, P., Dewelle, J., Lefranc, F., Wlodarczak, L., Thomas, S., A lactosylated steroid contributes in vivo therapeutic benefits in experimental models of mouse lymphoma and human glioblastoma (2006) J Med Chem, 49 (5), pp. 1800-1807
• Iurisci, I.D.A., Cumashi, A., Sherman, A.A., Tsvetkov, Y.E., Tinari, N., Piccolo, E., Synthetic inhibitors of galectin-1 and-3 selectively modulate homotypic cell aggregation and tumor cell apoptosis (2009) Anticancer Res, 29 (1), pp. 403-410
• Ito, K., Ralph, S., Inhibiting galectin-1 reduces murine lung metastasis with increased CD4+ and CD8+ T cells and reduced cancer cell adherence (2012) Clin Exp Metastasis, 29 (6), pp. 561-572
• Leffler, H., Nilsson, U.J., Low-molecular weight inhibitors of galectins (2012) Galectins and Disease Implications for Targeted Therapeutics, pp. 47-59. , Klyosov AA, Traber PG, editors. Washington, DC: Oxford University Press
• Lin, C.-I., Whang, E.E., Donner, D.B., Jiang, X., Price, B.D., Carothers, A.M., Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer (2009) Mol Cancer Res, 7 (10), pp. 1655-1662
• Öberg, C.T., Noresson, A.-L., Leffler, H., Nilsson, U.J., Synthesis of 3-amido-3-deoxy-β-d-talopyranosides: all-cis-substituted pyranosides as lectin inhibitors (2011) Tetrahedron, 67 (47), pp. 9164-9172
• Glinskii, O.V., Sud, S., Mossine, V.V., Mawhinney, T.P., Anthony, D.C., Glinsky, G.V., Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-l-leucine (2012) Neoplasia, 14 (1), pp. 65-73
• Glinsky, V.V., Kiriakova, G., Glinskii, O.V., Mossine, V.V., Mawhinney, T.P., Turk, J.R., Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo (2009) Neoplasia, 11 (9), pp. 901-909
• Glinsky, G.V., Price, J.E., Glinsky, V.V., Mossine, V.V., Kiriakova, G., Metcalf, J.B., Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines (1996) Cancer Res, 56 (23), pp. 5319-5324
• Rabinovich, G.A., Cumashi, A., Bianco, G.A., Ciavardelli, D., Iurisci, I., D'Egidio, M., Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis (2006) Glycobiology, 16 (3), pp. 210-220
• Zhang, W., Xu, P., Zhang, H., Pectin in cancer therapy: a review (2015) Trends Food Sci Technol, 44 (2), pp. 258-271
• Jiang, J., Eliaz, I., Sliva, D., Synergistic and additive effects of modified citrus pectin with two polybotanical compounds, in the suppression of invasive behavior of human breast and prostate cancer cells (2013) Integr Cancer Ther, 12 (2), pp. 145-152
• Jun, Y., Katz, A., PectaSol-C modified citrus pectin induces apoptosis and inhibition of proliferation in human and mouse androgen-dependent and-independent prostate cancer cells (2010) Integr Cancer Ther, 9 (2), pp. 197-203
• Jackson, C.L., Dreaden, T.M., Theobald, L.K., Tran, N.M., Beal, T.L., Eid, M., Pectin induces apoptosis in human prostate cancer cells: correlation of apoptotic function with pectin structure (2007) Glycobiology, 17 (8), pp. 805-819
• Guess, B.W., Scholz, M.C., Strum, S.B., Lam, R.Y., Johnson, H.J., Jennrich, R.I., Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study (2003) Prostate Cancer Prostatic Dis, 6 (4), pp. 301-304
• Grous, J.J., Redfern, C.H., Mahadevanm, D., Schindler, J., GCS-100, a galectin-3 antagonist, in refractory solid tumors: a phase I study (2006) 2006 ASCO Annual Meeting Proceedings, p. 13023. , June 2-6. Atlanta
• Chauhan, D., Li, G., Podar, K., Hideshima, T., Neri, P., He, D., A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells (2005) Cancer Res, 65 (18), pp. 8350-8358
• Zomer, E., Traber, P.G., Klyosov, A.A., Chekhova, E., (2013) Google Patents, , Composition of Novel Carbohydrate Drug for Treatment of Human Diseases
• Klyosov, A., Zomer, E., Platt, D., DAVANAT (GM-CT-01) and colon cancer: preclinical and clinical (phase I and II) studies (2012) Glycobiology and Drug Design, pp. 89-130. , Klyosov AA, editor. Washington, DC: Oxford University Press
• Newton-Northup, J., Dickerson, M., Ma, L., Besch-Williford, C., Deutscher, S., Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide (2013) Clin Exp Metastasis, 30 (2), pp. 119-132
• Deutscher, S.L., Figueroa, S.D., Kumar, S.R., Tumor targeting and SPECT imaging properties of an 111In-labeled galectin-3 binding peptide in prostate carcinoma (2009) Nucl Med Biol, 36 (2), pp. 137-146
• Dings, R.P.M., van der Schaft, D.W.J., Hargittai, B., Haseman, J., Griffioen, A.W., Mayo, K.H., Anti-tumor activity of the novel angiogenesis inhibitor anginex (2003) Cancer Lett, 194 (1), pp. 55-66
• Mayo, K.H., Dings, R.P.M., Flader, C., Nesmelova, I., Hargittai, B., van der Schaft, D.W.J., Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity (2003) J Biol Chem, 278 (46), pp. 45746-45752
• Zucchetti, M., Bonezzi, K., Frapolli, R., Sala, F., Borsotti, P., Zangarini, M., Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib (2013) Cancer Chemother Pharmacol, 72 (4), pp. 879-887
• Dings, R.P.M., Chen, X., Hellebrekers, D.M.E.I., van Eijk, L.I., Zhang, Y., Hoye, T.R., Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities (2006) J Natl Cancer Inst, 98 (13), pp. 932-936
• Cagnoni, A.J., Kovensky, J., Uhrig, M.L., Design and synthesis of hydrolytically stable multivalent ligands bearing thiodigalactoside analogues for peanut lectin and human galectin-3 binding (2014) J Org Chem, 79 (14), pp. 6456-6467
• Cumpstey, I., Salomonsson, E., Sundin, A., Leffler, H., Nilsson, U.J., Double affinity amplification of galectin-ligand interactions through arginine-arene interactions: synthetic, thermodynamic, and computational studies with aromatic diamido thiodigalactosides (2008) Chemistry, 14 (14), pp. 4233-4245
• Ito, K., Scott, S., Cutler, S., Dong, L.-F., Neuzil, J., Blanchard, H., Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress (2011) Angiogenesis, 14 (3), pp. 293-307
• Öberg, C.T., Blanchard, H., Leffler, H., Nilsson, U.J., Protein subtype-targeting through ligand epimerization: talose-selectivity of galectin-4 and galectin-8 (2008) Bioorg Med Chem Lett, 18 (13), pp. 3691-3694
• Leclere, L., Van Cutsem, P., Michiels, C., Anti-cancer activities of pH-or heat-modified pectin (2013) Front Pharmacol, 4, p. 128
• Nangia-Makker, P., Hogan, V., Honjo, Y., Baccarini, S., Tait, L., Bresalier, R., Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin (2002) J Natl Cancer Inst, 94 (24), pp. 1854-1862
• Pienta, K.J., Nailk, H., Akhtar, A., Yamazaki, K., Replogle, T.S., Lehr, J., Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin (1995) J Natl Cancer Inst, 87 (5), pp. 348-353
• Platt, D., Raz, A., Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin (1992) J Natl Cancer Inst, 84 (6), pp. 438-442
• Menachem, A., Bodner, O., Pastor, J., Raz, A., Kloog, Y., Inhibition of malignant thyroid carcinoma cell proliferation by Ras and galectin-3 inhibitors (2015) Cell Death Discov, 1, p. 15047
• Demotte, N., Wieërs, G., Van Der Smissen, P., Moser, M., Schmidt, C., Thielemans, K., A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice (2010) Cancer Res, 70 (19), pp. 7476-7488
• Demotte, N., Bigirimana, R., Wieërs, G., Stroobant, V., Squifflet, J.-L., Carrasco, J., A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor-infiltrating lymphocytes (2014) Clin Cancer Res, 20 (7), pp. 1823-1833
• Cotter, F., Smith, D.A., Boyd, T.E., Richards, D.A., Alemany, C., Loesch, D., Single-agent activity of GCS-100, a first-in-class galectin-3 antagonist, in elderly patients with relapsed chronic lymphocytic leukemia (2009) 2009 ASCO Annual Meeting Proceedings, p. 7006. , May 29-June 2. Orlando
• Zomer, E., Klyosov, A.A., Platt, D., Development of a galactomannan polysaccharide as a vehicle to improve the efficacy of chemotherapeutics (2012) Glycobiology and Drug Design, pp. 69-87. , Klyosov AA, editor. Washington, DC: Oxford University Press
• Miller, M.C., Klyosov, A., Platt, D., Mayo, K.H., Using pulse field gradient NMR diffusion measurements to define molecular size distributions in glycan preparations (2009) Carbohydr Res, 344 (10), pp. 1205-1212
• Miller, M.C., Klyosov, A., Mayo, K.H., The α-galactomannan davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain (2009) Glycobiology, 19 (9), pp. 1034-1045
• Zou, J., Glinsky, V.V., Landon, L.A., Matthews, L., Deutscher, S.L., Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion (2005) Carcinogenesis, 26 (2), pp. 309-318
• Yang, Y., Li, L., Zhou, Z., Yang, Q., Liu, C., Huang, Y., Targeting prostate carcinoma by G3-C12 peptide conjugated N-(2-Hydroxypropyl)methacrylamide copolymers (2014) Mol Pharm, 11 (10), pp. 3251-3260
• Yang, Y., Zhou, Z., He, S., Fan, T., Jin, Y., Zhu, X., Treatment of prostate carcinoma with (Galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates (2012) Biomaterials, 33 (7), pp. 2260-2271
• Sun, W., Li, L., Yang, Q., Shan, W., Zhang, Z., Huang, Y., G3-C12 peptide reverses galectin-3 from foe to friend for active targeting cancer treatment (2015) Mol Pharm, 12 (11), pp. 4124-4136
• Balan, V., Nangia-Makker, P., Raz, A., Galectins as cancer biomarkers (2010) Cancers (Basel), 2 (2), p. 592
• Wang, J.B., Wang, M.D., Li, E.X., Dong, D.F., Advances and prospects of anginex as a promising anti-angiogenesis and anti-tumor agent (2012) Peptides, 38 (2), pp. 457-462
• Mayo, K.H., From carbohydrate to peptidomimetic inhibitors of galectins (2012) Galectins and Disease Implications for Targeted Therapeutics, pp. 61-77. , Klyosov AA, Traber PG, editors. Washington, DC: Oxford University Press
• Griffioen, A.W., van der Schaft, D.W., Barendsz-Janson, A.F., Cox, A., Struijker Boudier, H.A., Hillen, H.F., Anginex, a designed peptide that inhibits angiogenesis (2001) Biochem J, 354, pp. 233-242
• Brandwijk, R.J.M.G.E., Dings, R.P.M., van der Linden, E., Mayo, K.H., Thijssen, V.L.J.L., Griffioen, A.W., Anti-angiogenesis and anti-tumor activity of recombinant anginex (2006) Biochem Biophys Res Commun, 349 (3), pp. 1073-1078
• Salomonsson, E., Thijssen, V.L., Griffioen, A.W., Nilsson, U.J., Leffler, H., The anti-angiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins (2011) J Biol Chem, 286 (16), pp. 13801-13804
• Astorgues-Xerri, L., Riveiro, M.E., Tijeras-Raballand, A., Serova, M., Rabinovich, G.A., Bieche, I., OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis (2014) Eur J Cancer, 50 (14), pp. 2463-2477
• Rezai, K., Durand, S., Lachaux, N., Raymond, E., Herait, P., Lokiec, F., OTX008 pharmacokinetics (PK) during the first-in-man phase I study in patients with advanced solid tumors (2013) Proceedings of the 104th Annual Meeting of the American Association for Cancer Research, , April 6-10, 2013. Washington, DC
• Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy (2012) Nat Rev Cancer, 12 (4), pp. 252-264
• Böcker, S., Laaf, D., Elling, L., Galectin binding to neo-glycoproteins: LacDiNAc conjugated BSA as ligand for human galectin-3 (2015) Biomolecules, 5 (3), p. 1671
• Cedeno-Laurent, F., Opperman, M., Barthel, S.R., Hays, D., Schatton, T., Zhan, Q., Metabolic inhibition of galectin-1-binding carbohydrates accentuates anti-tumor immunity (2012) J Invest Dermatol, 132 (2), pp. 410-420
• Gao, X., Zhi, Y., Zhang, T., Xue, H., Wang, X., Foday, A., Analysis of the neutral polysaccharide fraction of MCP and its inhibitory activity on galectin-3 (2012) Glycoconj J, 29 (4), pp. 159-165
• Martín-Satué, M., Marrugat, R., Cancelas, J.A., Blanco, J., Enhanced expression of a(1,3)-fucosyltransferase genes correlates with E-selectin-mediated adhesion and metastatic potential of human lung adenocarcinoma cells (1998) Cancer Res, 58 (7), pp. 1544-1550
• Brodt, P., Fallavollita, L., Bresalier, R.S., Meterissian, S., Norton, C.R., Wolitzky, B.A., Liver endothelial E-selectin mediates carcinoma cell adhesion and promotes liver metastasis (1997) Int J Cancer, 71 (4), pp. 612-619
• Eppihimer, M.J., Schaub, R.G., Soluble P-selectin antagonist mediates rolling velocity and adhesion of leukocytes in acutely inflamed venules (2001) Microcirculation, 8 (1), pp. 15-24
• Mirandola, L., Yu, Y., Cannon, M.J., Jenkins, M.R., Rahman, R.L., Nguyen, D.D., Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer (2014) Gynecol Oncol, 135 (3), pp. 573-579
• Croci, D.O., Salatino, M., Rubinstein, N., Cerliani, J.P., Cavallin, L.E., Leung, H.J., Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma (2012) J Exp Med, 209 (11), pp. 1985-2000
• Ouyang, J., Juszczynski, P., Rodig, S.J., Green, M.R., Donnell, E., Currie, T., Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders (2011) Blood, 117 (16), pp. 4315-4322

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------